Recruiting PHASE2 INTERVENTIONAL 3-arm NCT05013255

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

Sponsor: West Virginia University

Interventions Pioglitazone 15mg Pioglitazone 30 mg

Updated 8 times since 2021 Last updated: Apr 4, 2025 Started: Dec 23, 2021 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and Muscle Fatigue and is currently actively recruiting participants. West Virginia University leads this study, which shows 8 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

May 2025 — Present [monthly]

Recruiting PHASE2

Status: Unknown → Recruiting
Sep 2024 — May 2025 [monthly]

Unknown PHASE2
Aug 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Feb 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jan 2022 — Feb 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

West Virginia University

Data source: West Virginia University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Morgantown, United States